Your browser doesn't support javascript.
loading
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
Sokal, Aurélien; Bastard, Paul; Chappert, Pascal; Barba-Spaeth, Giovanna; Fourati, Slim; Vanderberghe, Alexis; Lagouge-Roussey, Pauline; Meyts, Isabelle; Gervais, Adrian; Bouvier-Alias, Magali; Azzaoui, Imane; Fernández, Ignacio; de la Selle, Andréa; Zhang, Qian; Bizien, Lucy; Pellier, Isabelle; Linglart, Agnès; Rothenbuhler, Anya; Marcoux, Estelle; Anxionnat, Raphael; Cheikh, Nathalie; Léger, Juliane; Amador-Borrero, Blanca; Fouyssac, Fanny; Menut, Vanessa; Goffard, Jean-Christophe; Storey, Caroline; Demily, Caroline; Mallebranche, Coralie; Troya, Jesus; Pujol, Aurora; Zins, Marie; Tiberghien, Pierre; Gray, Paul E; McNaughton, Peter; Sullivan, Anna; Peake, Jane; Levy, Romain; Languille, Laetitia; Rodiguez-Gallego, Carlos; Boisson, Bertrand; Gallien, Sébastien; Neven, Bénédicte; Michel, Marc; Godeau, Bertrand; Abel, Laurent; Rey, Felix A; Weill, Jean-Claude; Reynaud, Claude-Agnès; Tangye, Stuart G.
Afiliación
  • Sokal A; Necker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Chappert P; Imagine Institute, University Paris Cité, Paris, France.
  • Barba-Spaeth G; Department of Pediatrics, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Fourati S; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.
  • Vanderberghe A; Necker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.
  • Lagouge-Roussey P; INSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Meyts I; Institut Pasteur, University Paris Cité, CNRS UMR 3569, Structural Virology Unit, Paris, France.
  • Gervais A; Virology, Bacteriology, Hygiene and Mycology-Parasitology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
  • Bouvier-Alias M; INSERM U955, team 18. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Azzaoui I; INSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Fernández I; Departement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
  • de la Selle A; INSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Zhang Q; Departement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
  • Bizien L; Department of Immunology and Microbiology, Laboratory for Inborn Errors of Immunity, Department of Pediatrics, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium.
  • Pellier I; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Linglart A; Imagine Institute, University Paris Cité, Paris, France.
  • Rothenbuhler A; Virology, Bacteriology, Hygiene and Mycology-Parasitology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
  • Marcoux E; INSERM U955, team 18. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Anxionnat R; INSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.
  • Cheikh N; Departement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
  • Léger J; Institut Pasteur, University Paris Cité, CNRS UMR 3569, Structural Virology Unit, Paris, France.
  • Amador-Borrero B; Necker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.
  • Fouyssac F; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Menut V; Imagine Institute, University Paris Cité, Paris, France.
  • Goffard JC; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.
  • Storey C; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Demily C; Imagine Institute, University Paris Cité, Paris, France.
  • Mallebranche C; Pediatric Immuno-hemato-oncology Unit, Centre Hospitalier Universitaire Angers, Angers, France.
  • Troya J; University Angers, Nantes university, Centre Hospitalier Universitaire Angers, INSERM, CRCI2NA, SFR ICAT, Angers, France.
  • Pujol A; Departement of Pediatric Endocrinology, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Le Kremlin-Bicêtre, France.
  • Zins M; Departement of Pediatric Endocrinology, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Le Kremlin-Bicêtre, France.
  • Tiberghien P; Department of Pediatrics, Nord Franche Comté Hospital, Trévenans, France.
  • Gray PE; Department of Pediatrics, Besançon Hospital, Besançon, France.
  • McNaughton P; Department of Pediatrics, Besançon Hospital, Besançon, France.
  • Sullivan A; Department of Pediatric Endocrinology and INSERM NeuroDiderot, Referral Centre for Endocrine, Growth and Development diseases, Assistance Publique-Hôpitaux de Paris Nord, University of Paris, Paris, France.
  • Peake J; Department of Internal Medicine, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.
  • Levy R; Department of Pediatric Hemato-oncology, Childrens Hospital, Nancy University Hospital, Nancy, France.
  • Languille L; Department of Pediatrics, Mother-Child Hospital, Nantes, France.
  • Rodiguez-Gallego C; Department of Internal Medicine, Université Libre de Bruxelles-Hôpitaux Universitaire de Bruxelles, Erasme Hospital, Bruxelles, Belgique.
  • Boisson B; Departement of Pediatric Endocrinology, Robert Debré Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Gallien S; GénoPsy Referral Center, Centre de Référence de Maladies Rares Rare Disease with Psychiatric Epression, Le Vinatier Hospital, Bron, France.
  • Neven B; Pediatric Immuno-hemato-oncology Unit, Centre Hospitalier Universitaire Angers, Angers, France.
  • Michel M; University Angers, Nantes university, Centre Hospitalier Universitaire Angers, INSERM, CRCI2NA, SFR ICAT, Angers, France.
  • Godeau B; Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain.
  • Abel L; Neurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge-Hospital Duran i Reynals, Centro de Investigación Biomédica en Red de Enfermededas Raras U759, and Catalan Institution of Research and Advanced Studies, Barcelona, Spain.
  • Rey FA; University of Paris, University of Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, INSERM UMS11, Villejuif, France.
  • Weill JC; French Blood Agency, La Plaine Saint-Denis, France.
  • Reynaud CA; UMR1098 RIGHT, INSERM, French Blood Agency, Franche-Comté University, Besançon, France.
  • Tangye SG; Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia.
J Exp Med ; 220(1)2023 01 02.
Article en En | MEDLINE | ID: mdl-36342455
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos B / Interferón Tipo I / Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: J Exp Med Año: 2023 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos B / Interferón Tipo I / Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: J Exp Med Año: 2023 Tipo del documento: Article País de afiliación: Francia